LEIDEN, Netherlands,
April 19, 2023 /PRNewswire/
-- Pharming Group N.V. ("Pharming") (Euronext Amsterdam:
PHARM) (NASDAQ: PHAR) announces that Pharming's Chief Executive
Officer, Sijmen de Vries and Chief Financial Officer, Jeroen Wakkerman will attend the Van Lanschot
Kempen Life Sciences Conference on April
25 and 26, 2023 in Amsterdam, the
Netherlands.
Pharming's management will be available for one-to-one investor
meetings during the conference.
For more information about the conference, or to schedule a
one-to-one with Pharming's management team, please contact your Van
Lanschot Kempen representative, or send an email to Pharming's
Investor Relations team to investor@pharming.com.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is
a global biopharmaceutical company dedicated to transforming the
lives of patients with rare, debilitating, and life-threatening
diseases. Pharming is commercializing and developing an innovative
portfolio of protein replacement therapies and precision medicines,
including small molecules, biologics, and gene therapies that are
in early to late-stage development. Pharming is headquartered in
Leiden, Netherlands, and has
employees around the globe who serve patients in over 30 markets in
North America, Europe, the Middle
East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and find us on
LinkedIn.
For further public information, contact:
Pharming Group, Leiden, The
Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
Heather Robertson, Investor
Relations & Corporate Communications Manager
E: investor@pharming.com
FTI Consulting, London,
UK
Victoria Foster
Mitchell/Alex
Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon
Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Logo -
https://mma.prnewswire.com/media/2003587/Pharming_Group_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/pharming-to-attend-the-van-lanschot-kempen-life-sciences-conference-2023-301800319.html